Elite Pharmaceuticals launches generic methadone tablets

Elite Pharmaceuticals Inc. (OTCQB: ELTP) announced the commercial launch of its generic methadone hydrochloride tablets in 5 mg and 10 mg strengths.

The tablets are indicated for managing severe and persistent pain requiring opioid analgesics when alternative treatment options, including immediate-release opioids, are inadequate. The medication is also approved for detoxification and maintenance treatment of opioid addiction when used with appropriate social and medical services.

According to IQVIA data cited by the company, brand and generic methadone products generated approximately $22 million in annual retail sales in 2025.

Elite Pharmaceuticals operates as a specialty pharmaceutical company focused on developing and distributing niche generic products. The company specializes in oral, controlled-release drug products and operates a cGMP and DEA-registered research, development, and manufacturing facility in Northvale, New Jersey.

The company distributes multiple generic products nationwide under the Elite Laboratories Inc. label and has additional products licensed to TAGI Pharma.

You May Also Be Interested In

• IM Cannabis closes $250,000 convertible note deal with institutional investor
• Voya Financial warns shareholders of misleading TOMS Capital proxy filing
• QumulusAI signs profit-sharing GPU deal with agentic hedge fund